# EDGAR Filing Document

**Accession Number:** 0001557376
**File Stem:** 0001829126-26-005695
**Filing Date:** 2026-5
**Character Count:** 11553
**Document Hash:** a13c8db73a8326c9c4268037aff57734
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-005695.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001829126-26-005695

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260527

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zeo ScientifiX, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55008
- **FILM NUMBER:** 261022170

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **DATE OF NAME CHANGE:** 20180625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 27, 2026**

**<u>ZEO SCIENTIFIX, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-55008** | **47-4180540** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **3321 College Avenue, Suite 246<br> Davie, Florida** | **33314** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(888) 963-7881</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this "**Report**"), and unless otherwise indicated, the terms "**the Company**," "**ZEO**," "**we**," "**us**" and "**our**" refer to Zeo ScientifiX, Inc.

**Item 8.01 Other Events.**

On May 27, 2026, ZEO issued a press release announcing the formal launch of its Physician-Led Patient Masterclass program designed to help physicians mobilize their patient population and provide critical education to current and potential patients about regenerative medicine.

A copy of the press release is included as **Exhibit 99.1** to this Report.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits* 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated May 27, 2026](zeoscientifix_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: May 27, 2026 | **ZEO SCIENTIFIX, INC.** | **ZEO SCIENTIFIX, INC.** |
|  | By: | /s/ Ian T. Bothwell |
|  |  | Ian T. Bothwell<br> Chief Executive Officer and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**ZEO ScientifiX Launches Physician-Led Patient Masterclass Program<br> Following Grassroots Demand in the Southeast**

![](ex99-1_001.jpg)

*After training more than 600 physicians in under a year, the biologics research and products company now turns its focus to assisting physicians in educating their patients on the science of regenerative medicine.*

DAVIE, FLORIDA, May 27, 2026 -- ZEO ScientifiX, Inc. (OTCQB: ZEOX) ("ZEO ScientifiX" or the "Company"), a biologics research and products company dedicated to educating physicians on the science of regenerative medicine, today announced the formal launch of its Physician-Led Patient Masterclass program. The initiative formalizes a model that emerged organically in Vero Beach, Florida, and marks the Company's next strategic move: helping physicians mobilize their patient population and provide critical education to current and potential patients about regenerative medicine, something physicians have indicated has been in large demand.

In the past year alone, ZEO ScientifiX trained more than 600 physicians across the Southeast in the clinical application of regenerative therapies, including the utilization of stem cells for the three indications recently permitted under Florida law: pain management, wound care, and orthopedics. That network was built quietly and deliberately. What happened in Vero Beach made clear that it was time to activate it.

**A Room Full of Questions**

The program did not begin as a corporate initiative. Dr. Alita Sikora, a physician based in Vero Beach, who has attended prior ZEO ScientifiX's physician focused Masterclasses, decided to organize a local patient education event on her own. The objective was simple: inform patients in the community about regenerative medicine and potential ways regenerative medicine may be a viable health treatment option. The promotion was minimal. The response was not.

When ZEO ScientifiX Director of Growth Strategy Karlista Maroney attended one of the sessions, she found the room packed wall to wall. Chairs had run out. Patients came to understand their options for pain, wound care, and orthopedic conditions and to ask the questions a standard clinical appointment rarely leaves room for.

*"I walked into that room expecting a small gathering and found it packed wall to wall. They had run out of chairs. What Dr. Sikora built, without a campaign or a playbook, was proof that this conversation was already overdue. Patients want to understand their options. They want to know what is in the products being used in their care, where they come from, and whether it is right for them. That room told me exactly where we needed to go next. Our job is to set our physicians up to have that conversation at-scale. When patients are comfortable with their physician's knowledge of the subject and see their focus on safety and science they can make better decisions regarding their heath treatment options and ultimately the types of products they want to explore. Physicians need to be more proactive with their patients to help stimulate their practices. Demand for regenerative medicine is growing, and we intend to foster that every way possible. That is the model."*

**– Karlista Maroney, Director of Growth Strategy, ZEO ScientifiX**

**From Physician Network to Patient Movement**

The Masterclass program formalizes the structure Dr. Sikora demonstrated: a physician-hosted event designed to walk patients through the science, the appropriate use cases, and considerations of determining whether regenerative therapy is appropriate for their health plan. ZEO ScientifiX equips participating physicians with the educational framework and supporting materials. The clinical conversation remains entirely in the physician's hands.

The program also addresses a growing patient safety concern. As regenerative medicine expands in visibility, variability in product quality and sourcing has followed. ZEO ScientifiX sees physician-led education as a mechanism to help patients understand what questions to ask and what standards to hold their providers accountable to, regardless of where they ultimately seek care.

*"We built this physician network to drive clinical excellence and real practice growth. The Masterclass program is the logical extension of that work. An educated patient is a better patient. When physicians can have these conversations with their communities in depth, outcomes improve and trust is built. That is what sustainable growth looks like in this space. We are proud of what Dr. Sikora demonstrated and we are ready to scale it."*

**– Sean Vega-Stanton, General Manager, ZEO ScientifiX**

**About the Program**

The ZEO ScientifiX Physician-Led Patient Masterclass is open to physician partners across the Company's Florida network. Events are designed to be hosted locally, tailored to the community, and grounded in clinical education. Topics include the biological basis of regenerative therapies, appropriate use cases permittable under Florida law, patient selection criteria, and product sourcing and quality standards.

Physicians interested in hosting a Patient Masterclass event may contact ZEO ScientifiX directly.

**About ZEO ScientifiX (OTCQB: ZEOX)**

ZEO ScientifiX is a regenerative medicine biologics research and products company dedicated to advancing patient outcomes through physician-run clinics. ZEO supplies cutting-edge biologics and regenerative therapies, partnering with clinicians to drive clinical excellence and sustainable practice growth.

**Forward-Looking Statements**

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

**Media Contact**

ZEO ScientifiX, Inc.

Karlista Maroney

Director of Growth Strategy

ir@zeoscientifix.com

**# # #**